ClinicalTrials.gg
RecruitingNCT05916040TNTRectUpdated Dec 4, 2024

Total Neoadjuvant Treatment of Rectal Cancer by MRI-guided Radiotherapy

An observational study in Rectal Cancer, sponsored by Universitair Ziekenhuis Brussel. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Universitair Ziekenhuis Brussel · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.

Started
2024
with 5 others
Observational
7 of 56
4 open now
Primary completion
2025-06
later than 5 of 19 live
Registered
47th of 56
by date
Lead sponsor
3 of 56
Universitair Ziekenhuis Brussel

Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is one of 6 that started in 2024, is one of 7 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 47th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Rectal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The TNTRect trial is a prospective observational study that will evaluate the outcome of MR-guided stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost in a hypofractionated treatment of rectum cancer. Patients will be treated in 5 daily fractions of 5 Gy within an overall treatment time (OTT) of 5 days. A simultaneous integrated boost (SIB) till 30Gy will be delivered to the gross tumor volume. Patients will be treated with daily adaptive radiotherapy and online tumor gating on the MRIdian system (ViewRay Inc.). The aim of the study is to improve the complete clinical response rate to offer more patients an organ preserving approach.

The primary endpoint is patient response to the treatment, assessed by endoscopy and MRI, or by medical pathology reports after potential resection was performed. As secondary endpoints local control, disease-free survival, overall survival and the patient's quality of life \& hospital anxiety and depression will be measured.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Radiation therapy
  • MR-guided radiotherapy
  • Stereotactic body radiotherapy
  • Total Neo-adjuvant Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with rectal cancer aged 18 years or older.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced rectal cancer

Exclusion criteria

Exclusion Criteria:

  • Patients with unresectable disease at diagnosis
  • Patients with an performance status > 2
  • Patients not deemed fit for radiotherapy, chemotherapy or surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • TNTRect MRI-guided radiotherapy group with simultaneous integrated boost

    Interventions include having received MRI-guided therapy with simultaneous integrated boost on the gross tumor volume in patients with rectum cancer.

    Device: Radiotherapy with MRIdian with simultaneous integrated boost · Other: Questionnaires before, during and after radiotherapy

Interventions

  • DeviceRadiotherapy with MRIdian with simultaneous integrated boost

    radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost

    Also known as: Radiotherapy with MRIdian (ViewRay Inc.)

  • OtherQuestionnaires before, during and after radiotherapy

    Questionnaires consisting of 3 quality of life scales and 1 mental state scale: * EORTC QLQ-C30 * EORTC QLQ-CR29 * Low Anterior Resection Syndrome Score (LARS) questionnaire * Hospital Anxiety and Depression Scale (HADS) questionnaire

06

What researchers measure

Primary outcomes

  1. Response to therapy

    After radiotherapy and chemotherapy are administered, the patient will be evaluated for a potential watchful-waiting approach where, together with the patient, can be opted too not perform a TME (total mesorectal excision). This outcome measure registers if the therapy works.

    Time frame: up to 25 weeks after start of radiotherapy

Secondary outcomes

  1. Quality of life assessment via QLQ-C30

    Quality of life according to EORTC Quality of life Questionnaire QLQ-C30

    Time frame: from the start of radiotherapy until 5 years after treatment

  2. Colorectal specific quality of life assessment via QLQ-CR29

    Colorectal specific quality of life according to EORTC Quality of life Questionnaire QLQ-CR29

    Time frame: from the start of radiotherapy until 5 years after treatment

  3. Bowel functioning specific quality of life assessment via LARS score

    Bowel functioning quality of life according to Emmertsen and Lauberg's\[1\] Quality of life Questionnaire LARS. \[1\]: Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922-8. In that scientific publication, the authors introduced a practical and psychometrically robust instrument for examining bowel function (after surgery in rectal cancer), which reflects impact on quality of life.

    Time frame: from the start of radiotherapy until 5 years after treatment

  4. Anxiety and depression state via HADS

    Hospital Anxiety and Depression Scale (HADS) according to Zigmond and Snaith \[2\]. \[2\]: Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. In that scientific publication, the authors introduced a self-assessment scale to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic.

    Time frame: from the start of radiotherapy until 5 years after treatment

07

Study locations

1 of 1 sites recruiting
  • UZ Brussel - Dienst Radiotherapie
    Jette, Brussels Capital Region 1090, Belgium
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 7 months is below that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 23, 2023
StartActual
Nov 28, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2030
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05916040
Responsible party
Mark De Ridder (Principal Investigator, Prof., Universitair Ziekenhuis Brussel) — Principal investigator
First posted
Jun 23, 2023
Start date
Nov 28, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Dec 4, 2024

Study contacts

Mark De Ridder, MD
Contact
mark.deridder@uzbrussel.be
00324776041
Sven Van Laere, PhD
Contact
sven.vanlaere@uzbrussel.be
00324776041
Mark De Ridder, MD
principal investigator · Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion